The present study assessed the therapeutic potential of omeprazole (OME), the most
commonly prescribed proton pump inhibitor (PPI) used to treat gastroesophageal …

Renal toxicity is the primary factor that limits clinical use of cisplatin (CP). A previous study
showed that omeprazole (OME) protected against CP-induced toxicity in human renal …

The current study was designed to evaluate the potential abatement effect of pantoprazole
against cisplatin-induced nephrotoxicity and establishing the possible protective …

Cisplatin is used widely for the treatment of multiple solid tumors. Cisplatin‐induced
nephrotoxicity is caused by renal accumulation of cisplatin via human organic cation …

Nephrotoxicity is a major adverse reaction of cisplatin-based chemotherapy. Organic cation
transporter 2 (OCT2) which is located on the basement membrane of human proximal renal …

Acute kidney injury (AKI) is the main obstacle that limits the use of cisplatin in cancer
treatment. Proton pump inhibitors (PPIs), the most commonly used class of medications for …

Omeprazole, a proton pump inhibitor used to treat peptic ulcer and gastroesophageal reflux
disease, has been associated to chronic kidney disease and acute interstitial nephritis …

Oxidative stress significantly contributes to cisplatin (CP)-associated cytotoxicity, and use of
antioxidants could counteract such cytotoxic effects of CP. The major biochemical pathway …

Nitrooleic acid (OA‐NO2) is an endogenous lipid product which has novel signaling
properties, particularly the activation of peroxisome proliferator‐activated receptors. The …

Cisplatin is one of the most potent cytotoxic drug for the treatment of many types of cancer.
However, the side effects on normal tissues, particularly on the kidney, greatly limited its use …